O	0	1	A
O	2	12	randomized
O	13	18	cross
O	18	19	-
O	19	23	over
O	24	29	trial
O	30	32	to
O	33	39	detect
O	40	51	differences
O	52	54	in
O	55	58	arm
O	59	65	volume
O	66	71	after
B-intervention	72	75	low
I-intervention	75	76	-
I-intervention	77	80	and
I-intervention	81	86	heavy
I-intervention	86	87	-
I-intervention	87	91	load
I-intervention	92	102	resistance
I-intervention	103	111	exercise
O	112	117	among
O	118	126	patients
O	127	136	receiving
O	137	145	adjuvant
O	146	158	chemotherapy
O	159	162	for
O	163	169	breast
O	170	176	cancer
O	177	179	at
O	180	184	risk
O	185	188	for
B-condition	189	192	arm
I-condition	193	203	lymphedema
O	203	204	:
O	205	210	study
O	211	219	protocol
O	219	220	.

O	221	223	In
O	224	226	an
O	227	233	effort
O	234	236	to
O	237	243	reduce
O	244	247	the
O	248	252	risk
O	253	255	of
O	256	262	breast
O	263	269	cancer
O	269	270	-
O	270	277	related
O	278	281	arm
O	282	292	lymphedema
O	292	293	,
O	294	302	patients
O	303	306	are
O	307	315	commonly
O	316	323	advised
O	324	326	to
O	327	332	avoid
O	333	338	heavy
O	339	346	lifting
O	346	347	,
O	348	357	impacting
O	358	368	activities
O	369	371	of
O	372	377	daily
O	378	384	living
O	385	388	and
O	389	399	resistance
O	400	408	exercise
O	409	421	prescription
O	421	422	.

O	423	427	This
O	428	434	advice
O	435	440	lacks
O	441	449	evidence
O	449	450	,
O	451	455	with
O	456	458	no
O	459	470	prospective
O	471	478	studies
O	479	492	investigating
O	493	496	arm
O	497	503	volume
O	504	511	changes
O	512	517	after
O	518	528	resistance
O	529	537	exercise
O	538	542	with
O	543	548	heavy
O	549	554	loads
O	555	557	in
O	558	562	this
O	563	573	population
O	573	574	.

O	575	578	The
O	579	586	purpose
O	587	589	of
O	590	594	this
O	595	600	study
O	601	603	is
O	604	606	to
O	607	616	determine
O	617	622	acute
O	623	630	changes
O	631	633	in
O	634	637	arm
O	638	644	volume
O	645	650	after
O	651	652	a
O	653	660	session
O	661	663	of
O	664	667	low
O	667	668	-
O	669	672	and
O	673	678	heavy
O	678	679	-
O	679	683	load
O	684	694	resistance
O	695	703	exercise
O	704	709	among
O	710	715	women
O	716	726	undergoing
O	727	735	adjuvant
O	736	748	chemotherapy
O	749	752	for
O	753	759	breast
O	760	766	cancer
O	767	769	at
O	770	774	risk
O	775	778	for
O	779	782	arm
O	783	793	lymphedema
O	793	794	.

O	795	799	This
O	800	802	is
O	803	804	a
O	805	815	randomized
O	816	821	cross
O	821	822	-
O	822	826	over
O	827	832	trial
O	832	833	.

B-eligibility	834	839	Women
I-eligibility	840	849	receiving
I-eligibility	850	858	adjuvant
I-eligibility	859	871	chemotherapy
I-eligibility	872	875	for
I-eligibility	876	882	breast
I-eligibility	883	889	cancer
I-eligibility	890	893	who
I-eligibility	894	898	have
I-eligibility	899	908	undergone
I-eligibility	909	917	axillary
I-eligibility	918	923	lymph
I-eligibility	924	928	node
I-eligibility	929	939	dissection
O	940	944	will
O	945	947	be
O	948	957	recruited
O	958	962	from
O	963	977	rehabilitation
O	978	985	centers
O	986	988	in
O	989	992	the
B-location	993	1003	Copenhagen
O	1004	1008	area
O	1008	1009	.

O	1010	1022	Participants
O	1023	1027	will
O	1028	1030	be
O	1031	1039	randomly
O	1040	1048	assigned
O	1049	1051	to
O	1052	1058	engage
O	1059	1061	in
O	1062	1063	a
O	1064	1067	low
O	1067	1068	-
O	1069	1070	(
O	1070	1073	two
O	1074	1078	sets
O	1079	1081	of
O	1082	1084	15
O	1084	1085	-
O	1085	1087	20
O	1088	1098	repetition
O	1099	1106	maximum
O	1106	1107	)
O	1108	1111	and
O	1112	1117	heavy
O	1117	1118	-
O	1118	1122	load
O	1123	1124	(
O	1124	1129	three
O	1130	1134	sets
O	1135	1137	of
O	1138	1139	5
O	1139	1140	-
O	1140	1141	8
O	1142	1152	repetition
O	1153	1160	maximum
O	1160	1161	)
O	1162	1167	upper
O	1167	1168	-
O	1168	1177	extremity
O	1178	1188	resistance
O	1189	1197	exercise
O	1198	1205	session
O	1206	1210	with
O	1211	1212	a
O	1213	1216	one
O	1217	1221	week
O	1222	1226	wash
O	1226	1227	-
O	1227	1230	out
O	1231	1237	period
O	1238	1245	between
O	1246	1254	sessions
O	1254	1255	.

O	1256	1263	Changes
O	1264	1266	in
O	1267	1280	extracellular
O	1281	1286	fluid
O	1287	1288	(
O	1288	1289	L
O	1289	1290	-
O	1290	1293	Dex
O	1294	1299	score
O	1299	1300	)
O	1301	1304	and
O	1305	1308	arm
O	1309	1315	volume
O	1316	1317	(
O	1317	1319	ml
O	1319	1320	)
O	1321	1325	will
O	1326	1328	be
O	1329	1337	assessed
O	1338	1343	using
O	1344	1356	bioimpedance
O	1357	1369	spectroscopy
O	1370	1373	and
O	1374	1378	dual
O	1378	1379	-
O	1379	1385	energy
O	1386	1387	x
O	1387	1388	-
O	1388	1391	ray
O	1392	1406	absorptiometry
O	1406	1407	,
O	1408	1420	respectively
O	1420	1421	.

O	1422	1429	Symptom
O	1430	1438	severity
O	1439	1446	related
O	1447	1449	to
O	1450	1453	arm
O	1454	1464	lymphedema
O	1465	1469	will
O	1470	1472	be
O	1473	1483	determined
O	1484	1489	using
O	1490	1491	a
O	1492	1498	visual
O	1499	1507	analogue
O	1508	1513	scale
O	1514	1515	(
O	1515	1524	heaviness
O	1524	1525	,
O	1526	1534	swelling
O	1534	1535	,
O	1536	1540	pain
O	1540	1541	,
O	1542	1551	tightness
O	1551	1552	)
O	1552	1553	.

O	1554	1566	Measurements
O	1567	1571	will
O	1572	1574	be
O	1575	1580	taken
O	1581	1592	immediately
O	1593	1596	pre
O	1596	1597	-
O	1598	1601	and
O	1602	1606	post
O	1606	1607	-
O	1607	1615	exercise
O	1615	1616	,
O	1617	1620	and
O	1621	1623	24
O	1623	1624	-
O	1625	1628	and
O	1629	1631	72
O	1631	1632	-
O	1632	1637	hours
O	1638	1642	post
O	1642	1643	-
O	1643	1651	exercise
O	1651	1652	.

O	1653	1654	A
O	1655	1661	sample
O	1662	1666	size
O	1667	1669	of
B-total-participants	1670	1672	20
O	1673	1685	participants
O	1686	1689	was
O	1690	1700	calculated
O	1701	1706	based
O	1707	1709	on
O	1710	1717	changes
O	1718	1720	in
O	1721	1722	L
O	1722	1723	-
O	1723	1726	Dex
O	1727	1733	scores
O	1734	1741	between
O	1742	1750	baseline
O	1751	1754	and
O	1755	1757	72
O	1757	1758	-
O	1758	1763	hours
O	1764	1768	post
O	1769	1777	exercise
O	1778	1786	sessions
O	1786	1787	.

O	1788	1796	Findings
O	1797	1801	from
O	1802	1806	this
O	1807	1812	study
O	1813	1816	are
O	1817	1825	relevant
O	1826	1829	for
O	1830	1838	exercise
O	1839	1851	prescription
O	1852	1862	guidelines
O	1862	1863	,
O	1864	1866	as
O	1867	1871	well
O	1872	1874	as
O	1875	1890	recommendations
O	1891	1900	regarding
O	1901	1914	participating
O	1915	1917	in
O	1918	1928	activities
O	1929	1931	of
O	1932	1937	daily
O	1938	1944	living
O	1945	1948	for
O	1949	1954	women
O	1955	1964	following
O	1965	1972	surgery
O	1973	1976	for
O	1977	1983	breast
O	1984	1990	cancer
O	1991	1994	and
O	1995	1998	who
O	1999	2002	may
O	2003	2005	be
O	2006	2008	at
O	2009	2013	risk
O	2014	2016	of
O	2017	2027	developing
O	2028	2031	arm
O	2032	2042	lymphedema
O	2042	2043	.

O	2044	2051	Current
O	2052	2062	Controlled
O	2063	2069	Trials
O	2070	2084	ISRCTN97332727
O	2085	2086	.

O	2087	2097	Registered
O	2098	2100	12
O	2101	2109	February
O	2110	2114	2015
O	2114	2115	.
